Immunotherapy (e.g., Pembrolizumab) for Advanced Vulvar Cancer

Type: drug

Status: Investigational/Off-label for advanced vulvar cancer

Developer: Merck (Keytruda)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026